Novel Data Analysis Method Helps Uncover Hidden Disease Mechanisms.

New evidence on subjective impairments in cognitive performance

Neuroscientist Michel Goedert from Cambridge, UK, has received the "Hartwig Piepenbrock DZNE Prize", which is endowed with 60,000 euros.

DZNE study provides new insights into pathological phenomena of Alzheimer‘s disease.

A European research consortium led by DZNE will be investigating the neurodegenerative disease “Spinocerebellar Ataxia Type 3” (SCA3) in collaboration with the French pharmaceutical company Servier Laboratories.

In individuals with a genetic predisposition to Alzheimer’s disease, the immune cells of the brain – the “microglia” – start exerting a protective effect up to two decades before the first symptoms appear.

A study by DZNE and the University Hospital Bonn suggests that assessments of the eye’s retina could help to detect a loss of brain substance, i. e. “brain atrophy”.

DZNE scientist Markus Zweckstetter has been awarded 150,000 euros by the European Research Council to test potential drugs against Alzheimer’s disease in laboratory studies.

Findings by DZNE researchers and partners support the view that hyperactive immune cells in the brain can have a protective effect in the course of neurodegenerative diseases.

A consortium led by DZNE has been tasked with investigating whether patients with “dementia of unclear etiology” benefit from examination of the brain using amyloid PET.